•   
  •   
  •   

Health & FitFirst peanut allergy treatment to be reviewed by FDA panel

22:41  13 september  2019
22:41  13 september  2019 Source:   washingtonpost.com

Dairy Queen's Soft Serve Isn't Technically Ice Cream

Dairy Queen's Soft Serve Isn't Technically Ice Cream Dairy Queen's blizzards and cones are delicious. But the treats don't qualify as ice cream, at least according to the FDA.

The treatment can desensitize people with allergies to small amounts of peanuts but carries the risk of side effects. It is expected to be the first in a new wave A first -of-its-kind peanut allergy therapy will be scrutinized Friday by advisers to the Food and Drug Administration , who will assess whether the

Because treatment means consuming the food proteins they are allergic to, trial participants were much more likely to suffer an allergic reaction, like abdominal pain How facilities will become certified is still to be determined. As FDA moves to internal discussions, another peanut allergy treatment is

A first-of-its-kind peanut allergy therapy will be scrutinized Friday by advisers to the Food and Drug Administration, who will assess whether the drug’s ability to desensitize children to potentially life-threatening allergies outweighs its side effects. If approved, it would be the first of what’s expected to be a wave of new food allergy drugs that prevent a reaction, rather than simply treat one after the fact.

First peanut allergy treatment to be reviewed by FDA panel© Mypurgatoryyears/(iStock A Food and Drug Administration panel is set to review the safety and effectiveness of a peanut allergy treatment and recommend whether or not the agency should approve the drug.

After a year of treatment with the drug, Palforzia, most children in a large trial were able to tolerate the equivalent of two peanuts. But the drug caused a number of side effects — including an increase in allergic reactions and in the need for injections of epinephrine with a pen device to quell systemic responses. The therapy is not a cure; people will still need to avoid peanuts and carry emergency medication.

Neon Eyeshadow Has Never Been More Popular, But Is It Safe?

Neon Eyeshadow Has Never Been More Popular, But Is It Safe? In 2016, it was muted monochromatic makeup. 

New peanut allergy drug under FDA review could pave way for a new generation of allergy therapies.

An expert panel with the FDA voted for the approval of a new treatment option for children with peanut allergies . The treatment would be the first drug approved to prevent, or at Peanut allergies are one of the most common food allergies in the United States, affecting more than 1 .2 million children .

Palforzia, which is made by biotech company Aimmune Therapeutics, is aimed at reducing reactions when people are inadvertently exposed to peanuts, for example when eating a food that has been cross-contaminated. The company is seeking approval for administering the drug to children ages 4 to 17.

Subscribe to the Post Most newsletter: Today’s most popular stories on The Washington Post

“For a family with high anxiety and a significant burden of anxiety and fear from living with peanut allergy, this might give that extra buffer of safety,” said Marcus Shaker, a pediatric allergist at Dartmouth’s Geisel School of Medicine, who was not involved with the trial. “They’re still going to need to strictly avoid peanuts, but [this will help] to let go of some of the fear they may have.”

Experimental treatment could help people with severe peanut allergies

Experimental treatment could help people with severe peanut allergies Up to 80% of patients were able to tolerate a peanut or more after completing the immunotherapy.

The US has approved its first treatment for peanut allergies in children. The drug AR101, or Palforzia, uses oral immunotherapy, with children given After that, users must continue to take a daily dose to be able to tolerate accidental exposure. The treatment is not a cure and makers warn that

“ Peanut allergy affects approximately 1 million children in the U.S. and only 1 out of 5 of these children will outgrow their allergy . When used in conjunction with peanut avoidance, Palforzia provides an FDA -approved treatment option to help reduce the risk of these allergic reactions in children with

The committee’s deliberations will be closely watched, not only because it represents the first treatment for peanut allergy but also because the therapy — essentially a capsule of pharmaceutical grade peanut protein — is expected to be the first in a new generation of food allergy therapies that work by gradually increasing people’s exposure to the allergen. The advisory committee’s recommendation will guide the agency’s decision on whether to approve the treatment, but is not binding.

Despite the excitement, allergists said the treatment may not be appropriate for every patient. Treatment requires repeated office visits and regularly taking a drug that can trigger, in the short term, the very side effects it is aimed at preventing.

In a large trial of 551 people, including 496 children, one in 10 of the people who received the drug dropped out because of adverse events, which included abdominal pain, vomiting and systemic allergic reactions. In that trial, 14 percent of patients taking the drug had to use an epinephrine pen to quell a severe reaction — more than twice the rate of those taking a placebo.

Anti-smoking advocates bemoan "faltering" pace of FDA action

Anti-smoking advocates bemoan The FDA now faces lawsuits from its traditional allies: anti-smoking groups who are suing the agency to take action. "If you're not moving forward on your own with a clear goal in mind then, at some point, this is what happens," said Eric Lindblom, a lawyer at Georgetown University's O'Neill Institute who previously worked at the FDA's Center for Tobacco Products. Ten years after the center's launch, Lindblom and others say they underestimated the obstacles that would crowd FDA's path, including industry lawsuits, lobbying and the grinding pace of government bureaucracy.

A panel of experts is pushing the FDA to approve the first -ever treatment for children with peanut allergies . The drug is not a cure, rather, it's a daily

FDA advisory panel recommends approval of Aimmune peanut allergy therapy. We ’ re monitoring today’s meeting of the FDA advisory committee on Palforzia, a novel but controversial treatment that uses calibrated quantities of ingested peanut powder to protect people against severe peanut allergy .

“I think it may not be for every patient with peanut allergy. What I will be doing, and many of us as allergists will be doing, is having careful conversations with our patients about whether this is something they’re even interested in doing,” said Hemant Sharma, chief of the division of allergy and immunology at Children’s National Medical Center, who was involved in the trial.

Shaker said that it remains to be seen whether patients will accept the increased allergic reactions for the protection it confers against accidental exposure.

“I think we need more data on what it’s going to mean to patients and how it’s going to change their level of risk perception and change their quality of life,” Shaker said. He said the drug is “a little bittersweet for everybody. Everyone’s happy to see something happening, and yet it’s not what we asked for from Santa Claus.”

Some physicians already use escalating doses of inexpensive peanut flour to desensitize allergies, but federal approval of a drug would probably be covered by insurance and expand the use of the approach. Aimmune scientists say that an approved drug will also eliminate uncertainties about dosing that exist when using off-the-shelf peanut flour.

Vaping: The deaths, illnesses and controversies in the last year

  Vaping: The deaths, illnesses and controversies in the last year Get up to date on this growing -- but controversial -- industry.

Advisory panel vote could validate Aimmune’s product, pipeline. Peanuts move through a packaging Aimmune Therapeutics Inc.’s winding road to get its first allergy treatment approved by U.S “The FDA is really going to be charged with whether it can get comfortable with the longer-term safety,” he

Peanut allergy is the most common food allergy in the country and the standard treatment involves strictly monitoring what children eat. That approach doesn’t always work and accidental exposure is common, sending 1 in 4 children with peanut allergies to the emergency room every year.

Steve Tilles, senior director of medical affairs at Aimmune, said that it is not yet known how long people will need to stay on the drug, but he is hopeful that after a few years of treatment, people could discontinue the medication while remaining desensitized to peanuts.

Aimmune is also working on a therapy for egg allergies and tree nuts. Other researchers are working on a skin patch to treat peanut allergies or delivering a drug under the tongue.

Aimmune did not provide information on how much the drug would cost, but a recent analysis by ICER, a watchdog organization that focuses on drug pricing, concluded there was insufficient evidence that the drug was more beneficial than simply avoiding peanuts.

Read More:

New peanut allergy drug could herald a ‘sea change’ in treating food allergies, but is not a cure

The Big Number — 5.6 million youths deal with food allergies

FDA approves first generic version of EpiPen

Read More

Powder Keg: FDA bowed to industry for decades as alarms were sounded over talc .
Over the past 50 years, the FDA has relied upon - and often deferred to - industry even as outside experts and consumers repeatedly raised serious health concerns about talc powders and cosmetics, a Reuters investigation found. Again and again since at least the 1970s, the agency has downplayed the risk of asbestos contamination and declined to issue warnings or impose safety standards, according to documents produced in court proceedings and in response to public records requests. © Reuters/Faith Ninivaggi FILE PHOTO: Dr.

Topical videos:

usr: 3
This is interesting!